Avantor Inc. Common Stock (AVTR)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for a durable business at a sensible price. Avantor provides mission-critical lab products and consumables to biopharma and healthcare customers, so repeat demand and switching costs could give it a modest moat. But the numbers show a company in repair. In fiscal 2025, the year ended 2025-12-31, revenue was $6.6B and net income was -$530.2M, or diluted EPS -$0.78. That followed fiscal 2024 net income of $711.5M, or $1.04 per diluted share, and fiscal 2023 net income of $321.1M, or $0.47 per diluted share. The swing was driven partly by fiscal Q3 2025, the quarter ended 2025-09-30, when net loss was $711.8M and diluted EPS was -$1.04. Yet fiscal Q1 2026, the quarter ended 2026-03-31, showed net income of $43.3M and diluted EPS $0.06, so the latest filed quarter was profitable. Financial health is mixed. Trailing free cash flow is $454.7M, a 4.3% FCF yield, and a Piotroski F-Score of 8/9 suggests improving fundamentals. Debt-to-equity is 0.66, but Altman Z-Score is 1.57 and ROCE is only 2.69%, so returns on capital are weak. At $15.55 on 2026-10-13, P/B is 1.87 and EV/EBITDA is 124.07; the negative P/E reflects losses. The stock sits near the top of its 52-week range of $7.26-$16.38 and FairStock score is 48/100. This is a Lynch turnaround: loss in latest year after earlier profits. I would want evidence that the FY2025 loss was mostly non-recurring and that margins recover before calling it cheap.

In plain English: Avantor sells lab supplies and specialty materials to drugmakers, hospitals, and technology companies. The business is in a turnaround: it lost money in fiscal 2025 after earlier profits, but it still generates cash and carries a moderate debt load. At $15.55 on 2026-10-13, the price looks more hopeful than cheap because profits are weak and the stock is near the high end of its 52-week range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer